Seeking Alpha

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

ZÜRICH, Switzerland, Feb. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NLSP) (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon ...
Nasdaq

NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2

NLS Pharmaceutics (NLSP) provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed ...
Nasdaq

NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2

ZURICH, SWITZERLAND / ACCESSWIRE / March 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...